DT-061 is an orally bioavailable activator of protein phosphatase 2A (PP2A) and could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.
IC50&Target
PP2A.
体内研究
DT-061 (5 mg/kg, oral gavage, 4 weeks) shows single-agent activity in inhibiting H358 or H441 xenograft growth. Additionally, the combination of DT-061 and AZD6244 is more significantly efficient.
Animal Model:
6- to 8-week-old male BALB/c nu/nu mice injected with H441 cells (5 × 10).
Dosage:
5 mg/kg.
Administration:
Oral gavage for 4 weeks.
Result:
Showed activity in inhibiting tumor growth.
分子式
C25H23F3N2O5S
分子量
520.52
CAS号
1809427-19-7
运输条件
Room temperature in continental US; may vary elsewhere.